---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-000844"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T15:04:30.466404+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OS Therapies closes $6M private placement; funds operations into 2026

## Summary
- Raised $6.05M gross from sale of 1,512,500 units at $4.00/unit; each unit has Series A Convertible Preferred share and a warrant.
- Conversion price of preferred is $4.00; warrant exercise price is $4.40 per share.
- Cash runway expected into 2026; 98% of investment from pre-IPO or IPO investors.
- Data update from OST-HER2 Phase 2b trial in osteosarcoma to be announced during JP Morgan Healthcare Conference week.
- Company entered waiver with ELOC investor Square Gate Capital, including cash payments and issuance of additional shares.

## SEC filing metadata
- accession: 0001213900-25-000844
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/0001213900-25-000844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/ea0226635-8k_osthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-000844
- JSON: https://secwatch.observer/filing/0001213900-25-000844.json
- Plain text: https://secwatch.observer/filing/0001213900-25-000844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.